Cookies need to be enabled on your browser for this site to work properly. Please enable cookies before proceeding. More details
This site is optimized for Firefox (v1.x), Internet Explorer (v6.x), Chrome (v0.x), Safari (v3.x) and Netscape (v7.x) on Windows and Firefox (v1.x), Netscape (v7.x) and Safari (1.3) on the Macintosh.More details
JavaScript needs to be enabled on your browser for this site to work properly. Please enable JavaScript before proceeding. More details
 
Contact Us | Help  
LOGIN HERE [ REGISTER ]
Remember Me
 
Your Cart (0) CHECKOUT >>
E-mail to colleague Print-friendly page
Oral Antiepileptic Drug Sabril® Approved by FDA, Announced Lundbeck [Source: Lundbeck ]
(1) Add all to cart
[24-Aug-2009] Danish company Lundbeck announced on August 21 that the U.S. Food and Drug Administration (FDA) has granted two New Drug Application (NDA) approvals for Sabril® (vigabatrin) Tablets and Oral Solution. Sabril is indicated as monotherapy for pediatric patients one month to two years of age with infantile spasms (IS) for whom the potential benefits outweigh the potential risk of vision loss, and as adjunctive (add-on) therapy for adult patients with refractory complex...
Useful Links/Documents
Lundbeck
Press Release
H. Lundbeck A/S
Lundbeck Inc. announces FDA marketing approval for Sabril
      Page  1  of  1     
Price:  FREE
Infantile Spasms (Source: Lundbeck)
General views of children suffering from infantile spasms
TRT: 00:08:58 More